Skip to main content
Clinical Trials/CTRI/2020/12/029822
CTRI/2020/12/029822
Recruiting
未知

on-Interventional Study Protocol (non-PASS) with secondary use of data To understand the characteristics, treatment patterns and outcomes in nAMD across various centers in India

ovartis Healthcare Pvt Ltd0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: H55-H57- Other disorders of eye and adnexa
Sponsor
ovartis Healthcare Pvt Ltd
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Sponsor
ovartis Healthcare Pvt Ltd

Eligibility Criteria

Inclusion Criteria

  • Newly diagnosed nAMD patients
  • Patients (male or female) aged \>\=50 years of age at Index date
  • Patients diagnosed with nAMD in at least one eye
  • Patients with VA/OCT assessments at both baseline, Month 12 and Month 24
  • Patients treated with intravitreal injection of anti\-VEGF (received at least one anti\-VEGF injection during the post\-index follow\-up period and at least 2 visits with OCT in between Months 0\-12\).
  • Patients with minimum follow\-up period of 24 months. (received at least one anti\-VEGF injection and at least 1 visit with OCT in between Months 13\-24\)

Exclusion Criteria

  • Patients with dry AMD, geographic atrophy and other retinal diseases
  • Patients who were part of any other trial/ study
  • Patients undergoing additional ocular treatment along with Anti VEGF agents will be excluded.

Outcomes

Primary Outcomes

Not specified

Similar Trials